about
sameAs
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humansVariability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteersHow can the quality of medical data in pharmacovigilance, pharmacoepidemiology and clinical studies be guaranteed?Comparison of sympathetic modulation induced by single oral doses of mibefradil, amlodipine, and nifedipine in healthy volunteers.Universal definition of myocardial infarction.Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European SocPharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine.Reproducibility of non-invasive measurement and of short-term variability of blood pressure and heart rate in healthy volunteers.2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collabGenetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.The pharmacokinetics of perindopril in patients with liver cirrhosisEffect of oral administration of a new calcium channel blocking agent, bepridil on antipyrine clearance in man.2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of A2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with theCytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.Assessment of the effect of a single oral dose of telithromycin on sotalol-induced qt interval prolongation in healthy womenIn vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarialsPharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers.Influence of liver cirrhosis on sertraline pharmacokinetics.European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituteEuropean guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by repRelationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional studyAmiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicityModeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells.Pharmacology and mechanisms of action of new oral anticoagulants.Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study.Impact of negative inotropic drugs on accuracy of diastolic stress echocardiography for evaluation of left ventricular filling pressure.Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy.Comprehensive efforts to increase adherence to statin therapy.Postoperative analgesia and recovery course after major colorectal surgery in elderly patients: a randomized comparison between intrathecal morphine and intravenous PCA morphine.Effects of testosterone on ventricular repolarization in hypogonadic men.Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol.Rate-corrected QT interval: techniques and limitations.Rate-dependence of class III actions in the heart.GENomE wide analysis of sotalol-induced IKr inhibition during ventricular REPOLarization, "GENEREPOL study": Lack of common variants with large effect sizes.
P50
Q22242896-DD4ED456-4876-4D97-B55A-2EDAB469911FQ28238866-17191B64-B03C-4203-8971-39C30BBDB4FEQ28365919-F9562A2E-45C8-432C-9C95-113C1C68F3A8Q30663640-B188BB15-CC4B-417F-84DB-1C32F1118663Q32156882-E23F7290-0F76-478F-BEAB-AB51C08B5CE2Q34007701-793B92F5-FCCF-4480-B1DD-550DFCDE51E5Q34092420-EAC87D18-D6A0-47AD-BA79-6FA0482504D9Q34158513-CC968486-2807-4026-A38E-A186045F2FE6Q34346544-9BF5C7F1-EF3C-40E6-9AC1-0E21009FDCE6Q34351265-C9EE16DC-2019-45BB-9C35-F234F40CA191Q34368081-1A9444E7-47CE-4FDB-BF83-9BCB15AD0E83Q34397040-F5AE51B1-CCD7-4BDE-82E1-121EFBF9DF4BQ34402845-8D015553-72A6-4EE2-BDBF-2F057CC7B4B1Q34417081-69DC1167-453A-4A3C-8E25-C05F905024A1Q34431980-90DBB7F8-8798-44C5-BE64-37F9E04EF3CFQ34491530-0AFE8B0F-5588-4F0B-9A82-85F7F6002D01Q34636529-25D43EF4-AFA6-42E2-9A8A-739D3BE5D0D2Q34640762-C6399B9E-D077-4491-8C2F-D9DE2272EA78Q34910745-9BB44356-3776-4B01-9DED-182C8150FE7AQ35827140-CEFEBC24-F406-4D7B-8003-563B3770E4F3Q36018689-707ED6F1-1544-4651-A944-A807311911B8Q36053724-D70FDD1F-704A-41D7-A49A-15BAC060A2EAQ36093775-8A999452-BC7D-437B-9210-E7D85778DAC0Q36921887-76529062-78EA-4D12-8A78-C816771E223CQ36921892-5D530D58-929D-4D6E-8BA4-AE368CF03821Q37156281-1BE2E799-DEAD-4CB7-87F8-5C6B523D00F7Q37201673-A4C0601C-6F42-43DF-A33C-84A78DDE2575Q37613893-B12D1154-A1AC-4F89-B37A-36BA386FFC92Q38246726-6A2EBB58-9AA8-4645-AA85-85D8751D5744Q38403462-DF9AFD29-D109-46BE-8640-73DA370907E7Q38607586-323AFDB1-FE8F-4697-815F-19BE062D085AQ38912590-46C25C18-6532-4CA5-89D4-06822F2171F6Q39080414-66CDCAE0-CE45-4888-A7EA-ED7C7F0073B7Q39342913-F3E48061-1E7F-4ACD-AC9C-BE7BE94E0444Q39876838-3E1FB99D-0401-4471-862F-095588F9BDF4Q40442584-CC36AB8F-0B82-4688-9F8B-6B1DDC2C04E1Q40620240-555D5262-3564-43C3-804E-1B3CB07FB1EFQ40788117-F1B2E06C-ABB8-45D9-B95A-087E348B2127Q40889950-4903E913-4AFD-4C94-B7A8-B60D94008EFDQ41362902-36E51E41-36E1-466E-8879-2C68A661300D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
C. Funck-Brentano
@nl
C. Funck-Brentano
@sl
Christian Funck-Brentano
@en
Christian Funck-Brentano
@es
type
label
C. Funck-Brentano
@nl
C. Funck-Brentano
@sl
Christian Funck-Brentano
@en
Christian Funck-Brentano
@es
altLabel
C. Funck-Brentano
@en
prefLabel
C. Funck-Brentano
@nl
C. Funck-Brentano
@sl
Christian Funck-Brentano
@en
Christian Funck-Brentano
@es
P106
P21
P31
P496
0000-0003-0406-5189
P569
2000-01-01T00:00:00Z